carmustine has been researched along with Antibody Deficiency Syndrome in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sklar, CA | 1 |
Kim, TH | 1 |
Ramsay, NK | 1 |
Maze, R | 1 |
Kapur, R | 1 |
Kelley, MR | 1 |
Hansen, WK | 1 |
Oh, SY | 1 |
Williams, DA | 1 |
2 other studies available for carmustine and Antibody Deficiency Syndrome
Article | Year |
---|---|
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Carmustine; Child; Child, Preschoo | 1982 |
Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
Topics: Animals; Bone Marrow Transplantation; Carmustine; DNA, Complementary; Hematopoietic Stem Cells; Immu | 1997 |